Literature DB >> 12196083

Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis.

Francisco Arancibia1, Torsten T Bauer, Santiago Ewig, Josep Mensa, Julia Gonzalez, Michael S Niederman, Antoni Torres.   

Abstract

BACKGROUND: Initial empirical antimicrobial treatment of patients with community-acquired pneumonia (CAP) is based on expected microbial patterns. We determined the incidence of, prognosis of, and risk factors for CAP due to gram-negative bacteria (GNB), including Pseudomonas aeruginosa.
METHODS: Consecutive patients with CAP hospitalized in our 1000-bed tertiary care university teaching hospital were studied prospectively. Independent risk factors for CAP due to GNB and for death were identified by means of stepwise logistic regression analysis.
RESULTS: From January 1, 1997, until December 31, 1998, 559 hospitalized patients with CAP were included. Sixty patients (11%) had CAP due to GNB, including P aeruginosa in 39 (65%). Probable aspiration (odds ratio [OR], 2.3; 95% confidence interval [CI], 1.02-5.2; P =.04), previous hospital admission (OR, 3.5; 95% CI, 1.7-7.1; P<.001), previous antimicrobial treatment (OR, 1.9; 95% CI, 1.01-3.7; P =.049), and the presence of pulmonary comorbidity (OR, 2.8; 95% CI, 1.5-5.5; P =.02) were independent predictors of GNB. In a subgroup analysis of P aeruginosa pneumonia, pulmonary comorbidity (OR, 5.8; 95% CI, 2.2-15.3; P<.001) and previous hospital admission (OR, 3.8; 95% CI, 1.8-8.3; P =.02) were predictive. Infection with GNB was independently associated with death (relative risk, 3.4; 95% CI, 1.6-7.4; P =.002).
CONCLUSIONS: In our setting, in every tenth patient with CAP, an etiology due to GNB has to be considered. Patients with probable aspiration, previous hospitalization or antimicrobial treatment, and pulmonary comorbidity are especially prone to GNB. These pathogens are also an independent risk factor for death in patients with CAP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12196083     DOI: 10.1001/archinte.162.16.1849

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  86 in total

1.  Community acquired Pseudomonas pneumonia in an immune competent host.

Authors:  Mehrnaz Asadi Gharabaghi; Seyed Mojtaba Mir Abdollahi; Enayat Safavi; Seyed Hamid Abtahi
Journal:  BMJ Case Rep       Date:  2012-05-26

2.  [Competence network "community acquired pneumonia" (CAPNETZ). A first interim report].

Authors:  T Welte; R Marre; N Suttorp
Journal:  Internist (Berl)       Date:  2004-04       Impact factor: 0.743

3.  The Pseudomonas aeruginosa Chp chemosensory system regulates intracellular cAMP levels by modulating adenylate cyclase activity.

Authors:  Nanette B Fulcher; Phillip M Holliday; Erich Klem; Martin J Cann; Matthew C Wolfgang
Journal:  Mol Microbiol       Date:  2010-03-16       Impact factor: 3.501

4.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

5.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

6.  Bacteraemic community-acquired pneumonia due to Gram-negative bacteria: incidence, clinical presentation and factors associated with severity during hospital stay.

Authors:  L A Ruiz; A Gómez; C Jaca; L Martínez; B Gómez; R Zalacain
Journal:  Infection       Date:  2010-09-29       Impact factor: 3.553

7.  Impact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia.

Authors:  Elena Laserna; Oriol Sibila; Juan Felipe Fernandez; Diego Jose Maselli; Eric M Mortensen; Antonio Anzueto; Grant Waterer; Marcos I Restrepo
Journal:  Chest       Date:  2014-05       Impact factor: 9.410

8.  Impact of bacterial coinfection on clinical outcomes in pneumococcal pneumonia.

Authors:  S Kumagai; T Ishida; H Tachibana; Y Ito; A Ito; T Hashimoto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-06-10       Impact factor: 3.267

9.  Risk factors for pneumonia due to beta-lactam-susceptible and beta-lactam-resistant Pseudomonas aeruginosa: a case-case-control study.

Authors:  Mohammed J Al-Jaghbeer; Julie Ann Justo; William Owens; Joseph Kohn; P Brandon Bookstaver; Jennifer Hucks; Majdi N Al-Hasan
Journal:  Infection       Date:  2018-05-11       Impact factor: 3.553

Review 10.  Defining and predicting severe community-acquired pneumonia.

Authors:  Samuel M Brown; Nathan C Dean
Journal:  Curr Opin Infect Dis       Date:  2010-04       Impact factor: 4.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.